GlassScriptPhysician profile
James B Gettys
NPI 1912940586
$5,790.78
in general payments reported to CMS, 2019-2025
44 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $627 · 2021: $594 · 2022: $736 · 2023: $859 · 2024: $1,006 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151 · Education: $72.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.64 |
| Education | $72.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $521.29 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $431.51 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $376.00 | 2019-2023 | Otezla, Repatha, Aimovig |
| Pfizer INC. | $370.87 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.45 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $332.30 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $276.76 | 2019-2024 | |
| Lundbeck LLC | $245.80 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $211.58 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $195.68 | 2019-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $190.15 | 2022-2024 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $168.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.76 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gettys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.